J&J’s Centocor buys RespiVert

Centocor Ortho Biotech, a division of Johnson & Johnson (NYSE: JNJ), announced today that it has acquired acquired RespiVert, a private company that's developing small-molecule, inhaled therapies for the treatment of pulmonary diseases. RespiVert's two lead compounds are RV-568 and RV-1088, potential treatments for asthma, COPD and cystic fibrosis. Both programs are entering clinical trials.  RespiVert will continue to lead development of the two lung...